Urinary 18-Gene MyProstateScore 2.0 Test Can Detect Clinically Significant Prostate Cancer, Reduce Frequency Of Biopsies Compared With PCPTrc, Research Finds

Renal & Urology News (2/12, Persaud) reports, “The urinary 18-gene MyProstateScore 2.0 test can detect clinically significant prostate cancer and reduce the frequency of biopsies compared with the Prostate Cancer Prevention Trial risk calculator (PCPTrc), investigators” found. The researchers wrote, “The MyProstateScore 2.0 test measures 18 cancer-associated and high-grade cancer-associated genes in urine to provide a percentage likelihood of detecting GG ≥ 2 cancer on biopsy.” The findings were published in The Journal of Urology.